What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers

This Medical News article discusses how the first FDA-cleared blood test for Alzheimer biomarkers should and shouldn’t be used.

Authors

Publication Details

Journal
JAMA
Published
2025-06-13
DOI
https://doi.org/10.1001/jama.2025.9013
Citations
4
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
12.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers

Rita Rubin
4 citations
JAMA
Health Systems, Economic Evaluations, Quality of Life
12.52
article

What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers

Rita Rubin
article en
4 citations

Abstract

This Medical News article discusses how the first FDA-cleared blood test for Alzheimer biomarkers should and shouldn’t be used.

JAMAVol. 334(3)
Zero hunger
Openalex Percentile: Top 2%
Health Systems, Economic Evaluations, Quality of Life
12.52
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers — Rita Rubin · JAMA (2025) | TGRS Research Map | TGRS